GlobeNewswire Inc | Dec 29, 2021 08:30AM EST

December 29, 2021

CARLSBAD, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022. The Palisade Bio management team also will be hosting investor meetings during that period and talking about their lead program, LB1148. LB1148 has shown significant results in a Phase 2 trial with a 1.1-day improvement in return to bowel function following GI surgery in the mean.

Details of the presentations are as follows:

Event: H.C. Wainwright BIOCONNECT Virtual ConferenceDate: January 10-13, 2022Time: Presentation available starting at 7:00 a.m., ET on January 10, 2022 Event: Biotech ShowcaseDate: January 10-12, 2022Time: Presentation available starting at 8:00 a.m., PT on January 4, 2022

The presentations will be accessible in the investor relations section of the Palisades Bio website here.

About Palisade Bio

Palisade Bio is a clinical stage biopharmaceutical company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bios innovative lead asset LB1148, advancing towards Phase 3, is a protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier. For more information, please go towww.palisadebio.com.

Forward Looking StatementsThis communication contains forward-looking statements, including, without limitation, statements related to expectations regarding Palisades plans for future presentations at investor conferences. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisades current expectations. Forward-looking statements involve risks and uncertainties. Palisades actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Companys ability to advance its clinical programs and the uncertain and time-consuming regulatory approval process. Additional risks and uncertainties can be found in Palisade Bios Quarterly Report on Form 10-Q for the quarter endedSeptember30, 2021.Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisades expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Palisade Bio Investor Relations Contact:Dawn Hofmeisterir@palisadebio.comPalisade Bio Media Relations Contact:CORE IRJules Abrahamjulesa@coreir.com917-885-7378